RxDoctor Payments Data

Leonid Basovich, DO

Family Medicine · Citrus Heights, CANPI 1285626515

Payments from drug & device makers

$5,733in general payments, 2019–2025

Across 125 payments — averaging $45.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bayer$538
  • Novartis$490
  • Idorsia Pharmaceuticals US Inc$439
  • Lilly USA, LLC$400
  • Aimmune Therapeutics, Inc.$396
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,733 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$41,095
Medicare patients
131
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$42,120
JanuviaSitagliptin Phosphate29$25,950
Breo ElliptaFluticasone/Vilanterol40$15,478
CreonLipase/Protease/Amylase12$11,755
InvokanaCanagliflozin12$10,739
VascepaIcosapent Ethyl14$3,099
Diclofenac Sodium58$2,716
Aripiprazole14$2,380
Tamsulosin Hcl108$2,285
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,871
Atorvastatin Calcium206$1,551
Duloxetine Hcl25$1,161
Albuterol Sulfate HfaAlbuterol Sulfate65$1,157
Lisinopril187$1,142
Levothyroxine Sodium109$1,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$42,12062 claims
MerckJanuvia$37$25,95029 claims
GSKBreo Ellipta$165$15,47840 claims
AbbVieCreon$1,026$11,75512 claims
Johnson & JohnsonInvokana$224$10,73912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Citrus Heights

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →